SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies. Chapters:00:35 - Guest Introduction01:10 - SELECT Results Overview04:25 - Next Steps for Research07:15 - Mechanism of Action for CV Benefit09:00 - FLOW Trial Implications11:25 - Impact on Access15:00 - Future of Incretin Therapies21:45 - Predicting the Next 5-10 Years for Semaglutide

Episode metadata supplied by the publisher feed · Published Mar 2, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD

0:00 24:40

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 24 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on March 2, 2024.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!